Last reviewed · How we verify

NCT04674410

Utility of Empiric Antibiotics for Non-intubated Novel Coronavirus Diseases 2019 Patients

Withdrawn Last updated 22 March 2024
What this trial tests

trial testing Antibiotic in Covid19. Withdrawn.

Timeline
1 March 2020
Primary endpoint
31 December 2023
31 December 2023

Quick facts

Lead sponsorNational Institutes of Health Clinical Center (CC)
StatusWithdrawn
Study typeOBSERVATIONAL
Start date1 March 2020
Primary completion31 December 2023
Estimated completion31 December 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

National Institutes of Health Clinical Center (CC)

Who can join

18 and older, any sex, with Covid19 or Coronavirus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This retrospective analysis of inpatient data obtained from administrative and electronic medical records will investigate the role of empiric antibiotics on admission on the mortality for non-intubated patients presenting with Novel Coronavirus Diseases 2019 (COVID-19) associated pneumonia without extra-pulmonary sources of infection or septic shock.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Antibiotic

Trials testing the same drug.

Other recruiting trials for Covid19

Currently open trials in the same condition.

Other National Institutes of Health Clinical Center (CC) trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04674410.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing